INFORMATION IN THIS EXHIBIT IDENTIFIED BY BRACKETS IS CONFIDENTIAL AND HAS BEEN EXCLUDED PURSUANT TO ITEM 601(B)(10)(IV) OF REGULATION S-K BECAUSE IT (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO CASI PHARMACEUTICALS, INC. IF...License and Development Agreement • May 13th, 2021 • CASI Pharmaceuticals, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS LICENSE AND DEVELOPMENT AGREEMENT FOR CB-5339 (the “Agreement”) is dated as of March 5th, 2021 (the “Effective Date”) by and between Cleave Therapeutics, Inc., a corporation organized under the laws of Delaware having its place of business at 135 Main Street, Suite 1145, San Francisco, CA 94105 (“Cleave”), and CASI Pharmaceuticals, Inc., a corporation organized under the laws of Delaware having a place of business at 9620 Medical Center Drive, Suite 300, Rockville, Maryland 20850 (“CASI”). Cleave and CASI may be each referred to herein as a “Party” or, collectively, as “Parties.”
